A Prospective, Open-label Study To Assess The Pharmacokinetics, Safety & Efficacy Of Anidulafungin When Used To Treat Children With Invasive Candidiasis, Including Candidemia

Trial Profile

A Prospective, Open-label Study To Assess The Pharmacokinetics, Safety & Efficacy Of Anidulafungin When Used To Treat Children With Invasive Candidiasis, Including Candidemia

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2018

At a glance

  • Drugs Anidulafungin (Primary) ; Fluconazole
  • Indications Candidaemia; Candidiasis
  • Focus Adverse reactions; Registrational
  • Sponsors Pfizer
  • Most Recent Events

    • 22 Feb 2018 Status changed from recruiting to completed.
    • 15 Feb 2018 Planned End Date changed from 24 Apr 2018 to 28 Feb 2018.
    • 15 Feb 2018 Planned primary completion date changed from 24 Apr 2018 to 28 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top